Haeggquist & Eck Announces Investigation of PTC Therapeutics, Inc.

Haeggquist & Eck, LLP has commenced an investigation into PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT) to determine whether PTC Therapeutics and its Officers and Directors have violated the federal securities laws under the Securities Exchange Act of 1934. Shareholders who have suffered losses on their investment in PTC shares are encouraged to contact Zeldes Haeggquist & Eck to discuss their legal rights.

PTC, headquartered in South Plainfield, New Jersey, is a biopharmaceutical company focused on the development and commercialization of treatments for rare diseases.

On February 23, 2016, PTC announced that it received a Refuse to File letter from the United States Food and Drug Administration (the “FDA”) regarding PTC’s New Drug Application for the drug Translarna. Translarna is a protein restoration therapy designed to treat Duchenne muscular dystrophy, a form of muscular dystrophy that affects mostly men. The FDA stated in its Refuse to File letter that the application was not sufficiently complete to permit a substantive review.

Following this news, on February 23, 2016, PTC stock fell more than 55% on intraday trading.

What You Can Do
If you purchased shares of PTC stock, you may have legal claims against the Company and/or its Officers and Directors. If you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Amber L. Eck at 619-342-8000, or by email at ambere@zhlaw.com. There is no cost to you. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

By | 2017-05-24T20:16:24+00:00 February 24th, 2016|Uncategorized|Comments Off on Haeggquist & Eck Announces Investigation of PTC Therapeutics, Inc.